Eeva Test - Early Embryo Viability Assessment
At GCRM-Belfast we pride ourselves on innovation not imitation & always strive to offer our patients the best possible outcomes and the latest advances in IVF technology. As such were among the first fertility clinics in the world to offer the Early Embryo Viability Assessment (Eeva) test. We have recently upgraded our EEVA system to incorporate the latest advances in time lapse technology into our embryo selection algorithm giving patient best chance of having the baby they long for.
The Eeva test is the first and only non-invasive IVF test clinically proven to increase the accuracy of predicting viable embryos at an early stage. The Eeva test was developed based on landmark research conducted at Stanford University, in the United States, which discovered that early cell division timings are an accurate predictor of viability and underlying health of the embryo.
How does Eeva work?
At the heart of Eeva is intelligent computer vision software, which uses time-lapse imaging pictures of the developing embryos every five minutes, measuring scientifically and clinically validated cell-division parameters from video images. This enables assessment of critical and subtle differences in early embryo development and provides a prediction for the embryologist about which embryos are likely to grow to the blastocyst stage, a critical milestone in embryo development.
The video below illustrates how the Eeva test works:
Eeva Patient Video
What are the benefits of Eeva?
In traditional IVF the embryos need to be assessed by an embryologist under a microscope, hence the need to be removed from the incubator. Eeva is a non-invasive test that automatically captures images of the developing embryos which means they do not need to be removed from the incubator and subjected to the stresses of the outside environment. Identifying viable embryos in the first few days is one of the most critical factors that contribute to a successful live birth. By enabling real-time analysis of the embryos Eeva provides quantitative data on embryo development and this objective information helps improve the ability to select the most viable embryos for transfer and/or for freezing.
- Since its introduction in Jan 2014 through to Feb 2015 we have carried out over 180 IVF/ ICSI treatment cycles in patients who have elected to use Eeva
- When EEVA is used in conjunction with our Embryo selection MAP at GCRM-Belfast significant increases in clinical pregnancy and implantation rates were observed compared to conventional selection methods
- The additional objective information gained through the EEVA system allows embryologists & doctors to make informed decisions regarding which embryos to transfer or freeze to maximise your chance of a successful treatment
Is Eeva suitable for me?
Whether you are on your first IVF cycle or second, Eeva is suitable for all patients undergoing IVF treatment. By providing access to critical and subtle differences in the early stages of embryo development, Eeva provides embryologists and consultants with objective information about the underlying health of the embryo. This information is critical in making informed decisions about your treatment path. However, our data has shown has shown that the greatest increases in success rates are in those patients over 37 years of age. At GCRM-Belfast we put people before profits, for this reason we allow patients to decide based on the information we provide if the EEVA test is suitable for their treatment cycle rather than include it as standard and increase the base cycle or drug costs.
Dr Robbie Kerr (Laboratory Director at GCRM-BELFAST) said: "We were very proud to be the first clinic in Northern Ireland to utilise this new technology enabling couples to have a higher chance of successful treatment. GCRM-BELFAST strives to be one of the leading IVF Clinics in Europe, offering couples the latest innovations with the best possible outcomes. The Eeva test is a great example of the application of cutting edge research to clinical practice in order to improve patient outcomes.”